Current and future drug targets in weight management

Area of Science:

• Pharmacology and Endocrinology
• Metabolic Disease Research

Background:

• Obesity is a leading cause of chronic disease, with rising prevalence necessitating effective interventions.
• Limited availability of effective anti-obesity drugs drives significant research into novel molecular targets.
• Pharmacological weight management is complex due to robust energy homeostasis mechanisms.

Purpose of the Study:

• To review molecular strategies for reducing body weight and adipose tissue mass.
• To provide an overview of current and emerging pharmacological approaches to obesity treatment.

Main Methods:

• Review of scientific literature on molecular targets and drug development for obesity.
• Analysis of different therapeutic strategies including reduced lipid absorption, appetite suppression, and increased energy expenditure.
• Discussion of drugs in development, including those recently filed for approval and in clinical trials.

Main Results:

• Several novel weight-loss drug candidates are in development, targeting diverse pathways.
• New preparations include combinations like topiramate/phentermine, bupropion/naltrexone, and lorcaserin.
• Compounds are progressing through Phase II and III clinical trials, with future targets also identified.

Conclusions:

• Multiple molecular strategies are being investigated to combat the obesity epidemic.
• The pipeline for anti-obesity medications is expanding, with several promising candidates nearing approval.
• Continued research into novel targets is crucial for developing more effective weight management therapies.